Inventors with similar research interests:
Location History:
- Manhasset, NY (US) (2013)
- East Lansing, MI (US) (1986 - 2014)
- Holbrook, NY (US) (2016 - 2018)
- Parsippany, NJ (US) (2020)
- Murrieta, CA (US) (2010 - 2022)
- San Francisco, CA (US) (2019 - 2022)
- Menlo Park, CA (US) (2005 - 2023)
Company Filing History:
15 out of 37 
6 out of 11 
6 out of 10 
Years Active: 1986-2025
Areas of Expertise:
Title: Stephen A Boyd: Innovations in Ophthalmology
Introduction:
Stephen A Boyd, a resident of East Lansing, MI, has made significant contributions in the field of ophthalmology through his numerous patents. With 62 patents to his name, Boyd has demonstrated his commitment to advancing eye care treatments and drug delivery methods. In this article, we will explore some of his latest patents, highlight his career achievements, delve into his collaborations, and recognize his impact in the field of ophthalmology.
Latest Patents:
Boyd's most recent patents highlight his expertise in developing innovative treatments for glaucoma and drug delivery systems for the nasolacrimal system. His inventions have the potential to revolutionize the way these conditions are managed.
Glaucoma Treatment Device:
One of Boyd's recent patents involves a glaucoma treatment device. This invention focuses on implanting a shunt into the eye to create a fluid passageway between the anterior chamber and the suprachoroidal space. By doing so, the device helps to alleviate the increased intraocular pressure associated with glaucoma, providing potential relief for patients affected by this condition.
Drug Delivery Methods for Nasolacrimal System:
Boyd's patent for drug delivery methods specifically targets the nasolacrimal system. His invention involves an implant placed in the punctum, which releases therapeutic agents into the tear fluid over a sustained period. By focusing on controlled release, this innovative drug delivery system enhances the effectiveness of treatment within the specific eye region.
Career Highlights:
Boyd's remarkable contributions to ophthalmology extend beyond his patents. He has worked with renowned companies such as Mati Therapeutics Inc. and others, showcasing his dedication to both research and practical implementation of ophthalmic innovations. Boyd's expertise has likely extended his influence to various other projects, further solidifying his position as a leading figure in this field.
Collaborations:
Boyd has collaborated with notable experts in the field of ophthalmology, including Eugene de Juan, Jr, and Cary J Reich. These collaborative efforts indicate Boyd's dedication to interdisciplinary approaches and highlight his ability to work effectively with other experts in the field. Such collaborations contribute to the advancement and success of his innovative patents.
Conclusion:
Stephen A Boyd's contribution to the field of ophthalmology is evident through his impressive list of 62 patents. His latest inventions in glaucoma treatment and drug delivery methods for the nasolacrimal system showcase his continued commitment to finding solutions that enhance patient care. Alongside his successful collaborations and career highlights, Boyd has proven himself as a leading innovator in ophthalmology, bringing new hope to patients and advancing the field as a whole.